Testing a new daily inhaled powder for lung blood pressure disease

This trial is testing a medication called treprostinil palmitil inhalation powder (TPIP) to see if it helps people with pulmonary arterial hypertension—a condition where high pressure in the blood vessels of the lungs makes it hard to breathe and exercise. The medication is inhaled as a powder once a day, and researchers want to compare how well it works compared to a placebo (a dummy treatment with no active medicine). The main goal is to see if the medication improves how far people can walk and how well they can exercise.

People with pulmonary arterial hypertension often struggle with exercise and daily activities because their lungs can't pump blood efficiently. While there are some treatments available, researchers want to see if this new medication—taken just once a day by inhalation—can help patients do more and feel better than current options.